Free Trial

SCYNEXIS (SCYX) Competitors

SCYNEXIS logo
$0.70 +0.01 (+0.72%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$0.70 +0.00 (+0.43%)
As of 07/10/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYX vs. BHST, GNLX, TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, and MCRB

Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include BioHarvest Sciences (BHST), Genelux (GNLX), Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

SCYNEXIS vs. Its Competitors

BioHarvest Sciences (NASDAQ:BHST) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

BioHarvest Sciences has a net margin of -31.30% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BioHarvest Sciences-31.30% -307.04% -33.21%
SCYNEXIS -1,030.04%-53.47%-32.86%

BioHarvest Sciences currently has a consensus price target of $13.67, suggesting a potential upside of 89.29%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe BioHarvest Sciences is more favorable than SCYNEXIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioHarvest Sciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
SCYNEXIS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, BioHarvest Sciences had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for BioHarvest Sciences and 1 mentions for SCYNEXIS. BioHarvest Sciences' average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score.

Company Overall Sentiment
BioHarvest Sciences Neutral
SCYNEXIS Neutral

BioHarvest Sciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

54.4% of SCYNEXIS shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioHarvest Sciences has higher revenue and earnings than SCYNEXIS. BioHarvest Sciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioHarvest Sciences$27.70M4.28-$12.91M-$0.50-14.44
SCYNEXIS$3.75M7.28-$21.29M-$0.56-1.25

Summary

BioHarvest Sciences beats SCYNEXIS on 8 of the 15 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCYX vs. The Competition

MetricSCYNEXISMED IndustryMedical SectorNASDAQ Exchange
Market Cap$27.12M$2.43B$5.55B$9.04B
Dividend YieldN/A1.79%5.25%4.03%
P/E Ratio-1.259.3827.1820.14
Price / Sales7.28676.36419.0198.39
Price / CashN/A164.1737.5058.41
Price / Book0.484.698.085.60
Net Income-$21.29M$31.26M$3.16B$248.43M
7 Day Performance-4.24%6.81%4.66%5.47%
1 Month Performance-20.87%5.93%4.47%7.87%
1 Year Performance-68.47%-1.03%30.90%18.75%

SCYNEXIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCYX
SCYNEXIS
0.2947 of 5 stars
$0.70
+0.7%
N/A-64.5%$27.12M$3.75M-1.2560
BHST
BioHarvest Sciences
N/A$7.06
+2.3%
$13.67
+93.6%
N/A$113.33M$27.70M-14.12N/AHigh Trading Volume
GNLX
Genelux
1.8262 of 5 stars
$2.90
-2.7%
$17.75
+512.1%
+38.2%$112.45MN/A-3.3010
TARA
Protara Therapeutics
1.2063 of 5 stars
$2.80
-3.1%
$20.50
+632.1%
+35.1%$111.50MN/A-1.6330
ATOS
Atossa Genetics
1.6446 of 5 stars
$0.85
-0.4%
$6.17
+629.1%
-26.0%$109.68MN/A-4.038
HURA
TuHURA Biosciences
1.2942 of 5 stars
$2.40
-3.2%
$12.67
+427.8%
N/A$108.33MN/A0.00N/A
PROC
Procaps Group
N/A$0.95
-40.3%
N/A-62.0%$107.18M$409.92M0.004,900Gap Down
High Trading Volume
CCCC
C4 Therapeutics
1.5063 of 5 stars
$1.52
+2.7%
$12.00
+689.5%
-60.2%$105.09M$35.58M-1.03150
ANIX
Anixa Biosciences
2.9805 of 5 stars
$3.21
-0.6%
$9.00
+180.4%
+33.6%$104.04M$210K-8.455
MIST
Milestone Pharmaceuticals
3.0897 of 5 stars
$2.17
+11.9%
$7.00
+222.6%
+76.6%$103.72M$1M-2.7830News Coverage
High Trading Volume
MCRB
Seres Therapeutics
3.5758 of 5 stars
$10.85
-8.6%
$73.67
+579.0%
-37.4%$103.65M$126.32M-2.36330Positive News

Related Companies and Tools


This page (NASDAQ:SCYX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners